Real-world data from @ucalgary.bsky.social on #nirsevimab #Beyfortus: 79% effectiveness vs. #RSV hospitalization, 97% vs. ICU admission in infants. Severe RSV seen in otherwise healthy babies, supporting broad prevention rather than risk-based targeting alone. www.linkedin.com/posts/drmelv...
@vaccinologist.bsky.social
@newsen.bsky.social